Egalet (NASDAQ:EGLT) will announce its earnings results before the market opens on Monday, March 12th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Shares of Egalet (EGLT) opened at $0.72 on Monday. The company has a debt-to-equity ratio of -3.43, a quick ratio of 2.68 and a current ratio of 2.73. The stock has a market capitalization of $33.08, a P/E ratio of -0.21 and a beta of 0.58. Egalet has a 52-week low of $0.67 and a 52-week high of $5.60.

Several brokerages have weighed in on EGLT. Cantor Fitzgerald set a $7.00 target price on Egalet and gave the stock a “buy” rating in a research report on Thursday, November 16th. Stifel Nicolaus lowered Egalet from a “buy” rating to a “hold” rating and set a $1.50 target price on the stock. in a research report on Wednesday, January 3rd. Finally, Gabelli lowered Egalet from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $6.20.

ILLEGAL ACTIVITY NOTICE: “Egalet (EGLT) to Release Quarterly Earnings on Monday” was published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at

Egalet Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Earnings History for Egalet (NASDAQ:EGLT)

Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with's FREE daily email newsletter.